Annals of Oncology Advance Access originally published online on April 13, 2005
Annals of Oncology 2005 16(6):934-941; doi:10.1093/annonc/mdi189
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients
1 Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice; 2 INSERM U491, Faculté de Médecine de la Timone, Marseille, France; 3 Service de Radiothérapie, Institut Jules Bordet, Bruxelles, Belgique; 4 Service de Médecine Nucléaire, Centre Antoine Lacassagne; 5 Service ORL, Centre Antoine Lacassagne; 6 Service ORL du CHU de Nice; 7 Service de radiothérapie, Centre Antoine Lacassagne, Nice, France
* Correspondence to: Dr G. Milano, Oncopharmacology Unit, Centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 2, France. Tel: +33-4-92-03-15-53; Fax: +33-4-93-81-71-31; Email: gerard.milano{at}nice.fnclcc.fr
Background:: Epidermal growth factor receptor (EGFR) overexpression is associated with poor prognosis in head and neck cancer. The first intron of EGFR gene is polymorphic (9–23 CA repeats) and transcription declines when the number of repeats increases.
Patients and methods:: EGFR polymorphism (fluorescent genotyping) and expression (ligand-binding assay) were analyzed in tumors and normal tissues from 112 patients (100 men, 12 women; mean age 60 years).
Results:: The number of CA repeats varied from 15 to 22. Allelic distribution was trimodal (predominance of 16, 20 and 18 CA repeats). EGFR concentrations were significantly higher (P=0.02) in homozygous tumors as compared with heterozygous. Considering homozygous tumors, or classifying genotypes as short/long/intermediary (two alleles <17 versus two alleles 
17 versus others), no relationship was observed between tumoral EGFR genotype and expression. In the 76 tumors exhibiting at least one 16-CA allele, the length of the remaining allele was inversely correlated to EGFR expression (P=0.047). Tumoral EGFR expression, performance status (WHO criteria) and node involvement were independent predictors of specific survival (P <0.01). Tumoral or normal tissue EGFR genotype did not influence survival.
Conclusions:: Intron 1 EGFR polymorphism may be implicated in the regulation of EGFR expression in head and neck tumors.
Key words: epidermal growth factor receptor, gene polymorphism, head and neck cancer, prognostic markers
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Bergh Quo Vadis With Targeted Drugs in the 21st Century? J. Clin. Oncol., January 1, 2009; 27(1): 2 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Milano, M.-C. Etienne-Grimaldi, L. Dahan, M. Francoual, J.-P. Spano, D. Benchimol, M. Chazal, C. Letoublon, T. Andre, F.-N. Gilly, et al. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer Ann. Onc., December 1, 2008; 19(12): 2033 - 2038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al. Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al. Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-W. D. Tzeng, A. Frolov, N. Frolova, N. C. Jhala, J. H. Howard, S. M. Vickers, D. J. Buchsbaum, M. J. Heslin, and J. P. Arnoletti Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response Ann. Surg. Oncol., July 1, 2007; 14(7): 2150 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-S. Wang, P.-M. Chen, T.-J. Chiou, J.-H. Liu, J.-K. Lin, T.-C. Lin, H.-S. Wang, and Y. Su Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma Clin. Cancer Res., June 15, 2007; 13(12): 3597 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S-H. Ou, J. Zell, A Ziogas, and H Anton-Culver Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology Ann. Onc., January 1, 2007; 18(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Brandt, S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos, and H. Buerger Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response Clin. Cancer Res., December 15, 2006; 12(24): 7252 - 7260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kalyankrishna and J. R. Grandis Epidermal Growth Factor Receptor Biology in Head and Neck Cancer J. Clin. Oncol., June 10, 2006; 24(17): 2666 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Francoual, M.-C. Etienne-Grimaldi, J.-L. Formento, D. Benchimol, A. Bourgeon, M. Chazal, C. Letoublon, T. Andre, N. Gilly, J.-R. Delpero, et al. EGFR in colorectal cancer: more than a simple receptor Ann. Onc., June 1, 2006; 17(6): 962 - 967. [Abstract] [Full Text] [PDF]
|
|